Selection of Antibodies and Epitopes for Cardiac Troponin Immunoassays: Should We Revise Our Evidence-Based Beliefs?(Editorials) Selection of Antibodies and Epitopes for Cardiac Troponin Immunoassays: Should We Revise Our Evidence-Based Beliefs?(Editorials)

Selection of Antibodies and Epitopes for Cardiac Troponin Immunoassays: Should We Revise Our Evidence-Based Beliefs?(Editorials‪)‬

Clinical Chemistry 2005, May, 51, 5

    • $5.99
    • $5.99

Publisher Description

Cardiac troponins are regarded as the most specific and sensitive of the currently available diagnostic techniques for detection of myocardial damage, and the redefined criteria used to classify acute coronary syndrome patients presenting with ischemic symptoms as myocardial infarction patients are heavily predicated on an increased concentration of these markers in blood (1). Troponins also are the only markers identifying high-risk coronary patients who should be treated with antithrombotic agents, such as glycoprotein IIb/IIIa antagonists, and referred for invasive evaluation at the earliest opportunity. Not all troponin assays, however, are created equal; therefore, method selection by the clinical laboratory represents one of the major factors influencing the performance of this important biomarker for the diagnostic classification of an individual patient. Recent experimental data indicated that various commercially available methods have different limits of detection (and imprecision) for cardiac troponins (2). Thus, the percentage of patients recategorized from angina to myocardial infarction based on troponin results as a diagnostic criterion is also critically dependent on the performance of the assay used (3). Formulation of assay reagents is also important in minimizing analytic interference. Falsely increased or decreased troponin results may occur because of interferences with the antigen-antibody reaction. Interferences from rheumatoid factors or human anti-mouse antibodies, which can mimic troponin by linking the capture and detector antibodies, have been reported (4). Icteric and hemolyzed serum samples might also be a problem in certain immunoassays (5). Finally, an interfering blood component inhibiting the binding of some antibodies against epitopes in the central part of the cardiac troponin I (cTnI) molecule has been described (6,7). The use of antibodies recognizing these epitopes, which are known to be less susceptible to proteolysis, has been recommended for the development of cTnI assays (8), and many manufacturers have now endorsed this recommendation. Thus, the authors of studies on the negatively interfering factor predicted that many cTnI assays were likely to be affected by the factor. More and definitive experimental evidence was, however, required to permit identification and isolation of this component (9).

GENRE
Science & Nature
RELEASED
2005
1 May
LANGUAGE
EN
English
LENGTH
8
Pages
PUBLISHER
American Association for Clinical Chemistry, Inc.
SELLER
The Gale Group, Inc., a Delaware corporation and an affiliate of Cengage Learning, Inc.
SIZE
185.6
KB

More Books Like This

Clinical and Analytical Standardization Issues Confronting Cardiac Troponin I (Opinion) Clinical and Analytical Standardization Issues Confronting Cardiac Troponin I (Opinion)
1999
Reporting of Cardiac Troponin Concentrations (Letters) (Letter to the Editor) Reporting of Cardiac Troponin Concentrations (Letters) (Letter to the Editor)
2002
Risk Stratification in Acute Coronary Syndrome Using Cardiac Troponin I (Editorial) Risk Stratification in Acute Coronary Syndrome Using Cardiac Troponin I (Editorial)
2000
Role of Biomarkers in Risk Stratification of Acute Coronary Syndrome (Report) Role of Biomarkers in Risk Stratification of Acute Coronary Syndrome (Report)
2010
Contemporary Practice in Clinical Chemistry Contemporary Practice in Clinical Chemistry
2020
Handbook of Mediators in Septic Shock Handbook of Mediators in Septic Shock
2019

More Books by Clinical Chemistry

Lowering Cutoffs for Initial and Confirmation Testing for Cocaine and Marijuana: Large-Scale Study of Effects on the Rates of Drug-Positive Results (Drug Monitoring and Toxicology) Lowering Cutoffs for Initial and Confirmation Testing for Cocaine and Marijuana: Large-Scale Study of Effects on the Rates of Drug-Positive Results (Drug Monitoring and Toxicology)
1997
Myocardial Infarction Redefined: Role of Cardiac Troponin Testing (Editorial) Myocardial Infarction Redefined: Role of Cardiac Troponin Testing (Editorial)
2001
Distribution of Fasting Plasma Insulin, Free Fatty Acids, And Glucose Concentrations and of Homeostasis Model Assessment of Insulin Resistance in a Representative Sample of Quebec Children and Adolescents (Pediatric Clinical Chemistry) Distribution of Fasting Plasma Insulin, Free Fatty Acids, And Glucose Concentrations and of Homeostasis Model Assessment of Insulin Resistance in a Representative Sample of Quebec Children and Adolescents (Pediatric Clinical Chemistry)
2003
C677T and AI298C Polymorphisms of the Methylenetetrahydrofolate Reductase Gene: Incidence and Effect of Combined Genotypes on Plasma Fasting and Post-Methionine Load Homocysteine in Vascular Disease (Molecular Diagnostics and Genetics) C677T and AI298C Polymorphisms of the Methylenetetrahydrofolate Reductase Gene: Incidence and Effect of Combined Genotypes on Plasma Fasting and Post-Methionine Load Homocysteine in Vascular Disease (Molecular Diagnostics and Genetics)
2001
Acetylcholinesterase Activity and Biogenic Amines in Phenylketonuria (Technical Briefs) Acetylcholinesterase Activity and Biogenic Amines in Phenylketonuria (Technical Briefs)
2002
Homocysteine, 5, 10-Methylenetetrahydrofolate Reductase 677CT Polymorphism, Nutrient Intake, And Incident Cardiovascular Disease in 24 968 Initially Healthy Women (Molecular Diagnostics and Genetics) (Clinical Report) Homocysteine, 5, 10-Methylenetetrahydrofolate Reductase 677CT Polymorphism, Nutrient Intake, And Incident Cardiovascular Disease in 24 968 Initially Healthy Women (Molecular Diagnostics and Genetics) (Clinical Report)
2007